IGI Logo

Below is Perspective on Supriya Lifescience IPO listing By Ms. Sneha Poddar, AVP Retail Research, Motilal Oswal Financial Services

“Supriya Lifescience, a pharma API manufacturer, made a stellar debut with 55% gains, listing at Rs425/share against IPO price of Rs274, amidst positive market sentiments. It has a niche product portfolio of 38 APIs with focus primarily on diverse therapeutic areas. It has consistently been India’s largest exporter of certain niche products with well-balanced presence between regulated and semi/non-regulated markets. We like Supriya for its niche product portfolio, backward integrated business model and robust financials. It is well placed to tap opportunity in the pharma API market given its strong pipeline focused on further diversification.”

Above views are of the author and not of the website kindly read disclaimer